Fibrocell Science (FCSC) versus RXi Pharmaceuticals (RXII) Financial Review

Fibrocell Science (NASDAQ: FCSC) and RXi Pharmaceuticals (NASDAQ:RXII) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends and risk.

Analyst Recommendations

This is a breakdown of recent recommendations for Fibrocell Science and RXi Pharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fibrocell Science 0 0 3 0 3.00
RXi Pharmaceuticals 0 0 0 0 N/A

Fibrocell Science currently has a consensus target price of $5.00, indicating a potential upside of 657.58%. Given Fibrocell Science’s higher possible upside, equities research analysts plainly believe Fibrocell Science is more favorable than RXi Pharmaceuticals.

Earnings and Valuation

This table compares Fibrocell Science and RXi Pharmaceuticals’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Fibrocell Science $350,000.00 48.84 -$15.29 million ($1.83) -0.36
RXi Pharmaceuticals $20,000.00 366.17 -$8.99 million ($10.90) -0.28

RXi Pharmaceuticals has lower revenue, but higher earnings than Fibrocell Science. Fibrocell Science is trading at a lower price-to-earnings ratio than RXi Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Fibrocell Science has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500. Comparatively, RXi Pharmaceuticals has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500.

Profitability

This table compares Fibrocell Science and RXi Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Fibrocell Science N/A -640.52% -100.12%
RXi Pharmaceuticals N/A -157.22% -102.29%

Insider & Institutional Ownership

43.0% of Fibrocell Science shares are owned by institutional investors. Comparatively, 11.7% of RXi Pharmaceuticals shares are owned by institutional investors. 2.1% of Fibrocell Science shares are owned by insiders. Comparatively, 5.7% of RXi Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

About Fibrocell Science

Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults.

About RXi Pharmaceuticals

RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator. Its clinical development programs include RXI-109, an sd-rxRNA, for the treatment of dermal and ocular scarring, and Samcyprone for the treatment of such disorders as warts, alopecia areata, non-malignant skin tumors and cutaneous metastases of melanoma. Its pipeline is focused on approximately three areas, including dermatology, ophthalmology and cosmetic product development. Its RNAi therapies are designed to silence, or down-regulate, the expression of a specific gene that may be over-expressed in a disease condition and its immunotherapy agent treats diseases by inducing, enhancing or suppressing an immune response.

Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply